ABSTRACT
OBJECTIVE: Populations of Mexican American ancestry are at an increased risk for nonalcoholic fatty liver disease. The objective of this study was to determine whether loci in known and novel genes were associated with variation in aspartate aminotransferase (AST) (n = 3,644), alanine aminotransferase (ALT) (n = 3,595), and gamma-glutamyl transferase (GGT) (n = 1,577) levels by conducting the first genome-wide association study (GWAS) of liver enzymes, which commonly measure liver function, in individuals of Mexican American ancestry. METHODS: Levels of AST, ALT, and GGT were determined by enzymatic colorimetric assays. A multi-cohort GWAS of individuals of Mexican American ancestry was performed. Single-nucleotide polymorphisms (SNP) were tested for association with liver outcomes by multivariable linear regression using an additive genetic model. Association analyses were conducted separately in each cohort, followed by a nonparametric meta-analysis. RESULTS: In the PNPLA3 gene, rs4823173 (P = 3.44 × 10-10 ), rs2896019 (P = 7.29 × 10-9 ), and rs2281135 (P = 8.73 × 10-9 ) were significantly associated with AST levels. Although not genome-wide significant, these same SNPs were the top hits for ALT (P = 7.12 × 10-8 , P = 1.98 × 10-7 , and P = 1.81 × 10-7 , respectively). The strong correlation (r2 = 1.0) for these SNPs indicated a single hit in the PNPLA3 gene. No genome-wide significant associations were found for GGT. CONCLUSIONS: PNPLA3, a locus previously identified with ALT, AST, and nonalcoholic fatty liver disease in European and Japanese GWAS, is also associated with liver enzymes in populations of Mexican American ancestry.
Subject(s)
Alanine Transaminase/genetics , Aspartate Aminotransferases/genetics , Lipase/genetics , Membrane Proteins/genetics , Mexican Americans/genetics , Non-alcoholic Fatty Liver Disease/genetics , Adult , Female , Genetic Loci , Genome-Wide Association Study , Humans , Linear Models , Liver/enzymology , Male , Middle Aged , Non-alcoholic Fatty Liver Disease/ethnology , Polymorphism, Single Nucleotide , gamma-Glutamyltransferase/geneticsABSTRACT
No specific therapeutics are available for the treatment of sepsis-induced liver dysfunction, a clinical complication strongly associated with the high mortality rate of septic patients. This study investigated the effect of the essential oil of Hyptis crenata (EOHc), a lamiaceae plant used to treat liver disturbances in Brazilian folk medicine, on liver function during early sepsis. Sepsis was induced by the cecal ligation and puncture (CLP) model. Rats were divided into four groups: Sham, Sham+EOHc, CLP, and CLP+EOHc. EOHc (300 mg/kg) was orally administered 12 and 24 h after surgery. The animals were sacrificed for blood collection and liver tissue samples 48 h after surgery. Hepatic function was evaluated by measuring serum bilirubin, alkaline phosphatase (ALP), aspartate aminotransferase, and alanine aminotransferase (ALT) levels. The levels of malondialdehyde and the activity of superoxide dismutase, catalase, and GSH peroxidase (GSH-Px) were measured for assessment of oxidative stress. Liver morphology was analyzed by hematoxylin and eosin staining. EOHc normalized serum ALP, ALT, and bilirubin levels and inhibited morphological changes. In addition, we observed that EOHc inhibited elevation in hepatic lipid peroxidation and reduction of the glutathione peroxidase activity induced by sepsis. Our data show that EOHc plays a protective effect against liver injury induced by sepsis.
Subject(s)
Hyptis/chemistry , Liver Diseases/drug therapy , Oils, Volatile/administration & dosage , Plant Extracts/administration & dosage , Protective Agents/administration & dosage , Sepsis/complications , Alanine Transaminase/genetics , Alanine Transaminase/metabolism , Animals , Aspartate Aminotransferases/genetics , Aspartate Aminotransferases/metabolism , Brazil , Catalase/genetics , Catalase/metabolism , Humans , Liver/drug effects , Liver/enzymology , Liver/metabolism , Liver Diseases/etiology , Liver Diseases/genetics , Liver Diseases/metabolism , Male , Malondialdehyde/metabolism , Oxidative Stress/drug effects , Rats , Rats, Wistar , Superoxide Dismutase/genetics , Superoxide Dismutase/metabolismABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is the accumulation of extra fat in liver cells not caused by alcohol. Elevated transaminase levels are common indicators of liver disease, including NAFLD. Previously, we demonstrated that PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), and GCKR (rs780094) are associated with elevated transaminase levels in overweight/obese Mexican adults. We investigated the association between 288 SNPs identified in genome-wide association studies and risk of elevated transaminase levels in an admixed Mexican-Mestizo sample of 178 cases of NAFLD and 454 healthy controls. The rs2896019, rs12483959, and rs3810622 SNPs in PNPLA3 and rs1227756 in COL13A1 were associated with elevated alanine aminotransferase (ALT, ≥40IU/L). A polygenic risk score (PRS) based on six SNPs in the ADIPOQ, COL13A1, PNPLA3, and SAMM50 genes was also associated with elevated ALT. Individuals carrying 9-12 risk alleles had 65.8% and 48.5% higher ALT and aspartate aminotransferase (AST) levels, respectively, than those with 1-4 risk alleles. The PRS showed the greatest risk of elevated ALT levels, with a higher level of significance than the individual variants. Our findings suggest a significant association between variants in COL13A1, ADIPOQ, SAMM50, and PNPLA3, and risk of NAFLD/elevated transaminase levels in Mexican adults with an admixed ancestry. This is the first study to examine high-density single nucleotide screening for genetic variations in a Mexican-Mestizo population. The extent of the effect of these variations on the development and progression of NAFLD in Latino populations requires further analysis.
Subject(s)
Adiponectin/genetics , Alanine Transaminase/genetics , Aspartate Aminotransferases/genetics , Collagen Type XIII/genetics , Lipase/genetics , Membrane Proteins/genetics , Mitochondrial Proteins/genetics , Non-alcoholic Fatty Liver Disease/genetics , Adult , Aged , Alanine Transaminase/metabolism , Aspartate Aminotransferases/metabolism , Case-Control Studies , Ethnicity/genetics , Female , Gene Frequency , Genetic Predisposition to Disease , Humans , Male , Mexico , Middle Aged , Mitochondrial Precursor Protein Import Complex Proteins , Multifactorial Inheritance/genetics , Non-alcoholic Fatty Liver Disease/enzymology , Non-alcoholic Fatty Liver Disease/pathology , Polymorphism, Single NucleotideABSTRACT
For several decades, serum levels of alanine (ALT) and aspartate (AST) aminotransferases have been regarded as markers of liver injury, including a wide range of etiologies from viral hepatitis to fatty liver. The increasing worldwide prevalence of metabolic syndrome and cardiovascular disease revealed that transaminases are strong predictors of type 2 diabetes, coronary heart disease, atherothrombotic risk profile, and overall risk of metabolic disease. Therefore, it is plausible to suggest that aminotransferases are surrogate biomarkers of "liver metabolic functioning" beyond the classical concept of liver cellular damage, as their enzymatic activity might actually reflect key aspects of the physiology and pathophysiology of the liver function. In this study, we summarize the background information and recent findings on the biological role of ALT and AST, and review the knowledge gained from the application of genome-wide approaches and "omics" technologies that uncovered new concepts on the role of aminotransferases in human diseases and systemic regulation of metabolic functions. Prediction of biomolecular interactions between the candidate genes recently discovered to be associated with plasma concentrations of liver enzymes showed interesting interconnectivity nodes, which suggest that regulation of aminotransferase activity is a complex and highly regulated trait. Finally, links between aminotransferase genes and metabolites are explored to understand the genetic contributions to the metabolic diversity.
Subject(s)
Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Clinical Enzyme Tests , Genomics , Liver Diseases/diagnosis , Liver/enzymology , Metabolomics , Precision Medicine , Systems Biology , Alanine Transaminase/genetics , Animals , Aspartate Aminotransferases/genetics , Biomarkers/blood , Clinical Enzyme Tests/methods , Gene Regulatory Networks , Genetic Predisposition to Disease , Genome-Wide Association Study , Genomics/methods , Heredity , Humans , Liver Diseases/blood , Liver Diseases/epidemiology , Liver Diseases/genetics , Metabolomics/methods , Phenotype , Precision Medicine/methods , Predictive Value of Tests , Prognosis , Protein Interaction Maps , Risk Factors , Systems Biology/methodsABSTRACT
Malaria is a deadly infectious disease which affects millions of people each year in tropical regions. There is no effective vaccine available and the treatment is based on drugs which are currently facing an emergence of drug resistance and in this sense the search for new drug targets is indispensable. It is well established that vitamin biosynthetic pathways, such as the vitamin B6 de novo synthesis present in Plasmodium, are excellent drug targets. The active form of vitamin B6, pyridoxal 5-phosphate, is, besides its antioxidative properties, a cofactor for a variety of essential enzymes present in the malaria parasite which includes the ornithine decarboxylase (ODC, synthesis of polyamines), the aspartate aminotransferase (AspAT, involved in the protein biosynthesis), and the serine hydroxymethyltransferase (SHMT, a key enzyme within the folate metabolism).
Subject(s)
Aspartate Aminotransferases/metabolism , Glycine Hydroxymethyltransferase/metabolism , Malaria/enzymology , Ornithine Decarboxylase/metabolism , Animals , Antioxidants/metabolism , Aspartate Aminotransferases/genetics , Glycine Hydroxymethyltransferase/genetics , Humans , Malaria/genetics , Malaria/parasitology , Ornithine Decarboxylase/genetics , Plasmodium falciparum/enzymology , Plasmodium falciparum/genetics , Plasmodium falciparum/pathogenicity , Vitamin B 6/metabolismABSTRACT
PURPOSE: This study examined genetic associations of patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and liver aminotransferases in an extensively documented, randomly recruited Mexican American population at high risk of liver disease. METHODS: Two single nucleotide polymorphisms (SNP) in the PNPLA3 gene (i.e., rs738409 and rs2281135) were genotyped in 1532 individuals. Population stratification was corrected by the genotyping of 103 ancestry informative markers (AIMs) for Mexican Americans. RESULTS: Both PNPLA3 SNPs showed highly significant association with alanine aminotransferase (ALT) levels, but was also, in males, associated with aspartate aminotransferase (AST) levels. Haplotypic association test of the two SNPs suggested stronger genetic association with rs738409 than rs2281135. Obvious sex effects were observed: rs738409-sex interaction in ALT levels P = 8.37 x 10(-4); rs738409-sex interaction in AST levels P = 5.03 x 10(-3). CONCLUSIONS: This population study highlights a sex-specific association of PNPLA3 polymorphisms and elevated liver enzymes in a population-based study, independent of common pathological factors of the metabolic syndrome. The strong genetic association found in women ≤ 50 years old, but not in women > 50 years old, suggests that sex hormones may mediate the sex effect.
Subject(s)
Alanine Transaminase/genetics , Aspartate Aminotransferases/metabolism , Lipase/genetics , Liver Diseases/genetics , Membrane Proteins/genetics , Polymorphism, Single Nucleotide , Sex Characteristics , Adult , Age Factors , Alanine Transaminase/metabolism , Aspartate Aminotransferases/genetics , Female , Genotype , Humans , Lipase/metabolism , Liver/metabolism , Liver Diseases/metabolism , Male , Membrane Proteins/metabolism , Metabolic Syndrome/genetics , Metabolic Syndrome/metabolism , Mexican Americans , Middle AgedABSTRACT
PURPOSE: To determine the effects of oral L-glutamine (L-Gln) and the dipeptide L-alanyl-glutamine (L-Ala-Gln) upon the activity of the malate-aspartate shuttle in the rat distal small intestine following ischemia and reperfusion. METHODS: Seventy-two Wistar rats (350-400g), were randomized in 2 groups (n = 36): group S (Sham) and Group T (Treatment) and divided into 12 subgroups (n = 6): A-A6, and B1-B6. The subgroups A1-A3 were subjected to sham procedures at 30 and 60 minutes. Thirty minutes before the study, rats were treated with calcium caseinate, 0.5g/Kg (subgroups A1, A4, B1, B4), L-Gln, 0.5g / kg (subgroups A2, A5, B2 and B5) or L-Ala-Gln, 0.75g/Kg (subgroups A3, A6, B3, B6), administered by gavage. Ischemia was achieved by clamping the mesenteric vessels, delimiting a segment of bowel 5 cm long and 5 cm apart from the ileocecal valve. Samples were collected 30 and 60 minutes after start of the study for real-time PCR assay of malate dehydrogenases (MDH1-2) and aspartate-aminotransferases (GOT1-2) enzymes. RESULTS: Tissue MDH and GOT mRNA expression in intestinal samples from rats preconditioned with either L-Gln or L-Ala-Gln showed no significant differences both during ischemia and early reperfusion. CONCLUSION: Activation of the malate-aspartate shuttle system appears not to be the mechanism of glutamine-mediated elevation of glucose oxidation in rat intestine during ischemia/reperfusion injury.
Subject(s)
Aspartic Acid/metabolism , Glutamine/pharmacology , Intestine, Small/blood supply , Malates/metabolism , RNA, Messenger/blood , Reperfusion Injury/prevention & control , Animals , Aspartate Aminotransferases/blood , Aspartate Aminotransferases/genetics , Dipeptides/pharmacology , Disease Models, Animal , Intestine, Small/enzymology , Malate Dehydrogenase/blood , Malate Dehydrogenase/genetics , Random Allocation , Rats , Rats, Wistar , Real-Time Polymerase Chain Reaction , Reperfusion Injury/enzymology , Time FactorsABSTRACT
PURPOSE: To determine the effects of oral L-glutamine (L-Gln) and the dipeptide l-alanyl-glutamine (L-Ala-Gln) upon the activity of the malate-aspartate shuttle in the rat distal small intestine following ischemia and reperfusion. METHODS: Seventy-two Wistar rats (350-400g), were randomized in 2 groups (n = 36): group S (Sham) and Group T (Treatment) and divided into 12 subgroups (n = 6): A-A6, and B1-B6. The subgroups A1-A3 were subjected to sham procedures at 30 and 60 minutes. Thirty minutes before the study, rats were treated with calcium caseinate, 0.5g/Kg (subgroups A1, A4, B1, B4), L-Gln, 0.5g / kg (subgroups A2, A5, B2 and B5) or L-Ala-Gln, 0.75g/Kg (subgroups A3, A6, B3, B6), administered by gavage. Ischemia was achieved by clamping the mesenteric vessels, delimiting a segment of bowel 5 cm long and 5 cm apart from the ileocecal valve. Samples were collected 30 and 60 minutes after start of the study for real-time PCR assay of malate dehydrogenases (MDH1-2) and aspartate-aminotransferases (GOT1-2) enzymes. RESULTS: Tissue MDH and GOT mRNA expression in intestinal samples from rats preconditioned with either L-Gln or L-Ala-Gln showed no significant differences both during ischemia and early reperfusion. CONCLUSION: Activation of the malate-aspartate shuttle system appears not to be the mechanism of glutamine-mediated elevation of glucose oxidation in rat intestine during ischemia/reperfusion injury.
OBJETIVO: Determinar os efeitos da administração oral de L-glutamina (L-Gln) e do dipeptídeo L-alanil-glutamina (L-Ala-Gln) sobre a atividade do ciclo malato-aspartato no intestino delgado distal de ratos após isquemia/reperfusão. MÉTODOS: Setenta e dois ratos Wistar (350-400g) foram randomizados em 2 grupos (n = 36): T grupo S (Sham) e grupo (Tratamento) e distribuídos em 12 subgrupos (n = 6): A-A6, e B1-B6. Os subgrupos A1-A3 foram submetidos a procedimentos "sham" aos 30 e 60 minutos. Trinta minutos antes do estudo, os ratos foram tratados com caseinato de cálcio, 0,5 g/kg (subgrupos A1, A4, B1 e B4), L-Gln, 0,5 g/kg (subgrupos A2, A5, B2 e B5) ou L-Ala -Gln, 0,75g/kg (subgrupos A3, A6, B3, B6), administrado por gavagem. A isquemia foi obtida por pinçamento dos vasos mesentéricos, delimitando um segmento do intestino cinco centímetros de comprimento e 5 cm da válvula ileocecal. Amostras foram coletadas aos 30-60 minutos para ensaio de PCR em tempo real das enzimas malato desidrogenases (MDH1-2), aspartato-aminotransferase (GOT1-2). RESULTADOS: A expressão de MDH e GOT mRNA nas amostras provenientes do intestino delgado de ratos pré-condicionados com L-Gln ou L-Ala-Gln não apresentou diferenças significativas, tanto durante a isquemia como na fase inicial de reperfusão. CONCLUSÃO: Ativação do ciclo malato-aspartato não parece ser o mecanismo de elevação glutamina-mediada da oxidação da glicose no intestino de ratos durante a isquemia / reperfusão.
Subject(s)
Animals , Rats , Aspartic Acid/metabolism , Glutamine/pharmacology , Intestine, Small/blood supply , Malates/metabolism , RNA, Messenger/blood , Reperfusion Injury/prevention & control , Aspartate Aminotransferases/blood , Aspartate Aminotransferases/genetics , Disease Models, Animal , Dipeptides/pharmacology , Intestine, Small/enzymology , Malate Dehydrogenase/blood , Malate Dehydrogenase/genetics , Random Allocation , Rats, Wistar , Real-Time Polymerase Chain Reaction , Reperfusion Injury/enzymology , Time FactorsABSTRACT
Three genes encoding putative aspartate aminotransferases (ASATs) were identified in the Trypanosoma cruzi genome. Two of these ASAT genes, presumably corresponding to a cytosolic and mitochondrial isoform, were cloned and expressed as soluble His-tagged proteins in Escherichia coli. The specific activities determined for both T. cruzi isozymes were notably higher than the values previously reported for Trypanosoma brucei orthologues. To confirm these differences, T. brucei mASAT and cASAT were also expressed as His-tagged enzymes. The kinetic analysis showed that the catalytic parameters of the new recombinant T. brucei ASATs were very similar to those determined for T. cruzi orthologues. The cASATs from both parasites displayed equally broad substrate specificities, while mASATs were highly specific towards aspartate/2-oxoglutarate. The subcellular localization of the mASAT was confirmed by digitonin extraction of intact epimastigotes. At the protein level, cASAT is constitutively expressed in T. brucei, whereas mASAT is down-regulated in the bloodstream forms. By contrast in T. cruzi, mASAT is expressed along the whole life cycle, whereas cASAT is specifically induced in the mammalian stages. Similarly, the expression of malate dehydrogenases (MDHs) is developmentally regulated in T. cruzi: while glycosomal MDH is only expressed in epimastigotes and mitochondrial MDH is present in the insect and mammalian stages. Taken together, these findings provide evidence for a metabolically active mitochondrion in the mammalian stages of T. cruzi, and suggest that the succinate excreted by amastigotes more likely represents a side product of an at least partially operative Krebs cycle, than an end product of glycosomal catabolism.
Subject(s)
Aspartate Aminotransferases/genetics , Aspartate Aminotransferases/metabolism , Trypanosoma brucei brucei/enzymology , Trypanosoma cruzi/enzymology , Amino Acid Sequence , Animals , Aspartate Aminotransferases/isolation & purification , Aspartic Acid/metabolism , Cloning, Molecular , Escherichia coli/genetics , Gene Expression , Gene Expression Profiling , Gene Expression Regulation, Developmental , Isoenzymes/genetics , Isoenzymes/isolation & purification , Isoenzymes/metabolism , Ketoglutaric Acids/metabolism , Kinetics , Malate Dehydrogenase/biosynthesis , Microbodies/enzymology , Mitochondria/enzymology , Molecular Sequence Data , Phylogeny , Sequence Alignment , Substrate Specificity , Succinic Acid/metabolismABSTRACT
UNLABELLED: Recently, we reported that oxidative stress due to 3,3',5-triiodothyronine (T(3))-induced calorigenesis up-regulates the hepatic expression of mediators promoting cell protection. In this study, T(3) administration in rats (single dose of 0.1 mg/kg intraperitoneally) induced significant depletion of reduced liver glutathione (GSH), with higher protein oxidation, O(2) consumption, and Kupffer cell function (carbon phagocytosis and carbon-induced O(2) uptake). These changes occurred within a period of 36 hours of T(3) treatment in animals showing normal liver histology and lack of alteration in serum AST and ALT levels. Partial hepatic ischemia-reperfusion (IR) (1 h of ischemia via vascular clamping and 20 h reperfusion) led to 11-fold and 42-fold increases in serum AST and ALT levels, respectively, and significant changes in liver histology, with a 36% decrease in liver GSH content and a 133% increase in that of protein carbonyls. T(3) administration in a time window of 48 hours was substantially protective against hepatic IR injury, with a net 60% and 90% reduction in liver GSH depletion and protein oxidation induced by IR, respectively. Liver IR led to decreased DNA binding of nuclear factor-kappaB (NF-kappaB) (54%) and signal transducer and activator of transcription 3 (STAT3) (53%) (electromobility shift assay), with 50% diminution in the protein expression of haptoglobin (Western blot), changes that were normalized by T(3) preconditioning. CONCLUSION: T(3) administration involving transient oxidative stress in the liver exerts significant protection against IR injury, a novel preconditioning maneuver that is associated with NF-kappaB and STAT3 activation and acute-phase response.
Subject(s)
Ischemic Preconditioning/methods , Reperfusion Injury/prevention & control , Thyroid Gland/blood supply , Thyroid Gland/drug effects , Triiodothyronine/pharmacology , Acute-Phase Reaction/physiopathology , Alanine Transaminase/blood , Alanine Transaminase/genetics , Animals , Aspartate Aminotransferases/blood , Aspartate Aminotransferases/genetics , Gene Expression Regulation/drug effects , Glutathione/genetics , Glutathione/metabolism , Liver/metabolism , Liver/physiopathology , Male , NF-kappa B/genetics , NF-kappa B/metabolism , Oxidative Stress/drug effects , Rats , Rats, Sprague-Dawley , Reperfusion Injury/metabolism , Reperfusion Injury/physiopathology , STAT3 Transcription Factor/genetics , STAT3 Transcription Factor/metabolism , Signal Transduction/physiology , Thyroid Gland/metabolism , Thyroid Gland/physiopathologyABSTRACT
Aspartate is one of the compounds that induce the differentiation process of the non-infective epimastigote stage to the infective trypomastigote stage of the protozoan parasite Trypanosoma cruzi. l-aspartate is transported by both epimastigote and trypomastigote cells at the same rate, about 3.4 pmolmin(-1) per 10(7) cells. Aspartate transport is only competed by glutamate suggesting that this transport system is specific for anionic amino acids. Aspartate uptake rates increase along the parasite growth curve, by amino acids starvation or pH decrease. The metabolic fate of the transported aspartate was predicted in silico by identification of seven putative genes coding for enzymes involved in aspartate metabolism that could be related to the differentiation process.
Subject(s)
Aspartic Acid/metabolism , Trypanosoma cruzi/metabolism , Adenylosuccinate Synthase/genetics , Adenylosuccinate Synthase/metabolism , Animals , Asparaginase/genetics , Asparaginase/metabolism , Aspartate Aminotransferases/genetics , Aspartate Aminotransferases/metabolism , Aspartate-Ammonia Ligase/genetics , Aspartate-Ammonia Ligase/metabolism , Biological Transport , Catalysis , Computational Biology , Kinetics , Molecular Sequence Data , Trypanosoma cruzi/enzymology , Trypanosoma cruzi/geneticsABSTRACT
We studied the distribution of the acetylator phenotype in 47 patients aged 15 to 77 years receiving isonyazid as antituberculous therapy. 62% were fast and 32% slow acetylators. Ethnical, socio-economic and biologic factors were not related to acetylator type. The incidence of liver alterations, mainly elevated transaminase levels, was higher than reported in the literature and was not shown to be influenced by acetylator type. Adverse reactions to isonyacid were not related to drug serum levels.
Subject(s)
Acetyltransferases/metabolism , Antitubercular Agents/adverse effects , Acetylation , Acetyltransferases/genetics , Adolescent , Adult , Aged , Alkaline Phosphatase/genetics , Alkaline Phosphatase/metabolism , Antitubercular Agents/metabolism , Aspartate Aminotransferases/genetics , Aspartate Aminotransferases/metabolism , Chile , Female , Humans , Isoniazid/metabolism , Liver/drug effects , Liver/enzymology , Male , Middle Aged , Phenotype , Prospective StudiesSubject(s)
Adolescent , Adult , Middle Aged , Humans , Male , Female , Acetyltransferases , Antitubercular Agents/adverse effects , Phenotype , Acetylation , Aspartate Aminotransferases/genetics , Aspartate Aminotransferases/metabolism , Acetyltransferases/genetics , Acetyltransferases/metabolism , Chile , Prospective Studies , Alkaline Phosphatase/genetics , Alkaline Phosphatase/metabolism , Isoniazid/metabolism , Liver/drug effects , Liver/enzymology , Antitubercular Agents/metabolismABSTRACT
By means of starch gel electrophoresis and specific staining, molecular forms of aspartate aminotransferase and soluble esterases have been investigated in liver extracts of individuals from a population of Zenaida auriculata. Four alleles at the locus corresponding to soluble or cytoplasmic aspartate aminotransferase have been demonstrated. Distribution of phenotypes in the population is in perfect agreement with that expected according to the Hardy - Weinberg law. A large incidence of variants of two fractions of esterases has been found. This variability is, with all probability, genetically determined. The importance of this type of studies to assess genetic structure and dynamics of animal population is emphasized.